Clinical trial
A Crossover Safety Study of Ferumoxytol Versus Placebo
NCT00255450 · AMAG Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00255450 |
|---|---|
| Title | A Crossover Safety Study of Ferumoxytol Versus Placebo |
| Official title | A Double Blind, Placebo Controlled, Crossover Design, Multicenter Study of Intravenous Ferumoxytol Compared With Placebo |
| Lead sponsor | AMAG Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anemia |
| Intervention type | Drug |
| Interventions | ferumoxytol or placebo |
| Enrollment | 750 |
| Start date | Jan 1, 2005 |
| Completion | Aug 1, 2006 |
| First posted | Nov 21, 2005 |
| Last update posted | Nov 11, 2008 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: